<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="pharmaceutics-12-00171-t003" orientation="portrait" position="float">
 <object-id pub-id-type="pii">pharmaceutics-12-00171-t003_Table 3</object-id>
 <label>Table 3</label>
 <caption>
  <p>Examples of approved nanoplatforms for drug delivery by the FDA, EMA and other organizations (updated table, after Singh et al. [
   <xref rid="B185-pharmaceutics-12-00171" ref-type="bibr">185</xref>]).
  </p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Name</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Company/Approval Year/Country/Organization</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Nanoplatform. Benefits</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Virus</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Route of Administration</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">REF</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Epaxal
     <sup>®</sup>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Crucell (former Berna Biotech Ltd.);
     <break/>1994 Switzerland
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Virosomes (around 150 nm 
     <italic>spherical liposomal vesicles</italic>)—intrinsic adjuvant properties; reduced toxicity and superior tolerability;
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HAV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intramuscular vaccine</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B186-pharmaceutics-12-00171" ref-type="bibr">186</xref>,
     <xref rid="B187-pharmaceutics-12-00171" ref-type="bibr">187</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inflexal
     <sup>®</sup> V
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Crucell (former Berna Biotech Ltd.);
     <break/>1997 Switzerland
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Virosomes (around 150 nm 
     <italic>spherical liposomal vesicles</italic>)—biodegradable and biocompatible adjuvant systems; unwanted side effects; superior immune response;
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intramuscular vaccine</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B187-pharmaceutics-12-00171" ref-type="bibr">187</xref>,
     <xref rid="B188-pharmaceutics-12-00171" ref-type="bibr">188</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PegIntron
     <sup>®</sup>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Schering Corporation, 2001, U.S., FDA</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEG-interferon alfa-2b (polymeric NPs) —31.000 Daltons molecules; superior protein stability;</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subcutaneous</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B189-pharmaceutics-12-00171" ref-type="bibr">189</xref>] 
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pegasys
     <sup>®</sup>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Genentech, 2002, U.S. FDA</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEG-interferon alfa-2a (polymeric NPs)—31.000 Daltons molecules; superior protein stability;</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HBV, HCV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subcutaneous</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B190-pharmaceutics-12-00171" ref-type="bibr">190</xref>,
     <xref rid="B191-pharmaceutics-12-00171" ref-type="bibr">191</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influvac
     <sup>®</sup> Plus
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BGP Pharma ULC,
     <break/>2005, Canada
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Virosome vaccine</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intramuscular
     <break/>vaccine
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B192-pharmaceutics-12-00171" ref-type="bibr">192</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VivaGel
     <sup>®</sup> BV
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Starpharma, Australia;
     <break/>Mundipharma, Europe, 2019
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dendrimer (astodrimer sodium—SPL7013) incorporated in a water-based vaginal gel, acting as a targeting antiviral biofilm.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV, HSV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Topically Applied (Vaginal gel)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B193-pharmaceutics-12-00171" ref-type="bibr">193</xref>]
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
